Annals of Oncology 10:1441-1449, 1999
© 1999 European Society for Medical Oncology
research-article |
Primary gastric non-Hodgkin's lymphoma: Clinical features, management, and prognosis of 185 patients with diffuse large B-cell lymphoma
Section of Medical Oncology, Department of Oncology, King Faisal Specialist Hospital & Research Center Riyadh, Saudi Arabia
Correspondence to: Ezzeldin M. Ibrahim, MD, Department of Oncology (MBC #64), King Faisal Specialist Hospital and Research Center, PO Box 3354, Riyadh 11211, Kingdom of Saudi Arabia. E-mail: ezzibrahim{at}kfshrc.edu.sa
Background: Primary gastric non-Hodgkin's lymphoma (PG-NHL) is common in Saudi Arabia. This has prompted the analysis of a large series of patients with PG-NHL having high-grade diffuse large B-cell lymphoma (DLCL) in order to define the clinical features and outcome of this disease.
Patients and methods: The data of all adult patients in the series with PG-NHL having DLCL histology were retrospectively reviewed. Patients were eligible if they had biopsy-confirmed diagnoses obtained by endoscopy or following laparotomy.
Results: Over a 16-year period, 185 patients with DLCL PG-NHL were identified and their data were reviewed. Patients had a median age of 54 years. In 53% of them only one initial therapeutic modality was given, while 47% were managed by a multi-modality approach. One hundred forty patients (76%), 19 (10%), and 26 (14%) attained complete remission (CR), partial remission, and no response/progressive disease, respectively. Multivariate analysis showed that poor performance status and advanced stage were negatively associated with the likelihood of attaining CR. Over a median follow-up of 54 months, 118 (64%) of the patients were alive and disease-free, 17 (9%) were alive with evidence of disease, and the remaining 50 (27%) were dead. The projected 5-year and 10-year overall survivals (OS) (±SD) were 68% (±4%) and 61% (±6%), respectively. The Cox proportional hazards model identified the same variables of response as adverse prognostic factors of survival. Using the influence of performance status, and stage, a prognostic index was constructed to recognize three prognostically distinctive risk categories with overall survival proportions of 87%, 61%, and 45%, respectively. The unadjusted International Prognostic Index, however, failed to classify patients into prognostically meaningful risk strata. Of the 140 patients who achieved CR, the median disease-free survival (DFS) was not reached, but the predicted 5- and 10-year DFS were 82% and 75%, respectively. A multivariate analysis identified poor performance status as the only independent prognostic covariate that adversely influenced DFS. Our analysis showed that compared with single-modality management, multi-modality strategy attained significantly higher CR, and advantageous OS and DFS.
Conclusions: This large series characterized the clinicopathologic features and outcome of patients with DLCL PG-NHL. Performance status, and stage significantly influenced patient outcome. A prognostic index was developed and it identified three prognostically distinctive risk groups; however, prospective validation is warranted.
gastric, large cell, non-Hodgkin's lymphoma
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  F Di Raimondo, L Caruso, G Bonanno, P Naso, A Chiarenza, P Fiumara, A Bari, G. Palumbo, A Russo, and R Giustolisi Is endoscopic ultrasound clinically useful for follow-up of gastric lymphoma? Ann. Onc., February 1, 2007; 18(2): 351 - 356. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Ibrahim and A. Ezzat Failure of the International Prognostic Index to prognosticate outcome in primary gastric DLBC lymphoma Ann. Onc., May 1, 2004; 15(5): 841 - 841. [Full Text] [PDF]
|
|
|
|
|
|
J.-C. Delchier Reply to Letter to the Editor on "Surgical resection plus chemotherapy versus chemotherapy alone: comparison of two strategies to treat diffuse large B-cell gastric lymphoma", by M. Binn, A. Ruskone-Fourmestraux, E. Lepage et al. (Ann Oncol 2003; 14: 1751-1757) Ann. Onc., May 1, 2004; 15(5): 842 - 842. [Full Text] [PDF]
|
|
|
|
|
|
M. Binn, A. Ruskone-Fourmestraux, E. Lepage, C. Haioun, A. Delmer, P. Aegerter, A. Lavergne, C. Guettier, and J.-C. Delchier Surgical resection plus chemotherapy versus chemotherapy alone: comparison of two strategies to treat diffuse large B-cell gastric lymphoma Ann. Onc., December 1, 2003; 14(12): 1751 - 1757. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Raderer, A. Chott, J. Drach, C. Montalban, B. Dragosics, U. Jager, A. Puspok, C. Osterreicher, and C. C. Zielinski Chemotherapy for management of localised high-grade gastric B-cell lymphoma: how much is necessary? Ann. Onc., July 1, 2002; 13(7): 1094 - 1098. [Abstract] [Full Text] [PDF]
|
|